^
Association details:
| Biomarker: | HER-2 overexpression |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Herceptin is a HER2/neu receptor antagonist indicated for...The treatment of HER2-overexpressing metastatic gastric or
gastroesophageal junction adenocarcinoma.
Test:
Source:
Excerpt:
Herceptin should only be used in patients with metastatic gastric cancer whose tumours have HER2 overexpression...
Source:
Excerpt:
Trastuzumab should be added to first-line chemotherapy for HER2 overexpressing metastatic adenocarcinoma
Source:
Title:
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Published date:
08/19/2010
Excerpt:
Trastuzumab, a monoclonal antibody against human epidermal growth factor receptor 2 (HER2; also known as ERBB2), was investigated in combination with chemotherapy for first-line treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer...Median follow-up was 18.6 months (IQR 11-25) in the trastuzumab plus chemotherapy group and 17.1 months (9-25) in the chemotherapy alone group. Median overall survival was 13.8 months (95% CI 12-16) in those assigned to trastuzumab plus chemotherapy compared with 11.1 months (10-13) in those assigned to chemotherapy alone (hazard ratio 0.74; 95% CI 0.60-0.91; p=0.0046).
Secondary therapy:
cisplatin + 5-fluorouracil; cisplatin + capecitabine
DOI:
10.1016/S0140-6736(10)61121-X
Trial ID:
Source:
Title:
Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.
Excerpt:
...Patients with cancers overexpressing HER2 by Immunohistochemistry test( IHC) 3+ and/or IHC 2+ with positive gene amplification by FISH (confirmation on archived tissue needed) 3....
Trial ID:
Source:
Title:
Investigation of the Proportion of Human Epidermal Growth Factor Receptor 2 Protein Overexpression of Gastric Adenocarcinoma and Prognostic Effect of HER2, and Analysis of Practice Pattern of Herceptin Use in Stage IV Gastric Cancer
Excerpt:
...The proportion of HER2 overexpression in gastric cancer patients...
Trial ID:
More C2 evidence
Source:
Title:
A pilot study of trastuzumab monotherapy in patients who progressed under a previous platinum-based or 5-fluoropyrimidin-based chemotherapy in metastatic or locally advanced gastric cancer
Excerpt:
...Age > 18 years (ethnical group: any; gender: female and male) Progression under or after one prior platinum-based or 5-fluoropyrimidine-based chemotherapy in metastatic disease At least four weeks from the last platinum-based or 5-fluoropyrimidin-based chemotherapy Histological proof of gastric adenocarcinoma including adenocarcinoma of the gastroesophageal junction with HER2 overexpression of the primary or metastatic tumor tissue determined by immunohistochemistry and FISH (Score IHC 3+ or Score IHC 2+ and FISH +) Metastatic (M1) or locally advanced disease At least one measurable lesion evaluable for response (RECIST criteria) Estimated life expectancy of > 3 months ECOG Performance Status: 0-2 Adequate cardiac function: LVEF > 50% (detected by echocardiogram) Absolute neutrophil count > 1,500/µl Absolute platelet count > 100,000 /µl Serum total bilirubin: < 2.0 x upper normal limit (UNL) Creatinine < 1.5 x UNL AST and ALT < 2.5 x UNL; < 5 x UNL in patients with documented liver metastases Alkaline phosphatase: < 2.5 UNL Negative pregnancy test Willingness to give written informed consent, written consent for data protection and willingness to participate and comply with the study...
Trial ID:
Source:
Title:
PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer
Excerpt:
...HER2 overexpression and/or amplification as determined by immunohistochemistry (3+) or FISH (≥2.0)...
Trial ID:
Source:
Title:
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Excerpt:
...- Patients must have a histologically proven Her2 overexpressing malignancy as determined by any standardized assay currently in clinical use...
Trial ID:
Source:
Title:
Efficacy and Safety of Trastuzumab, Capecitabine y Oxaliplatine as Treatment Gastric Cancer Metastatic (HER2)Positive
Excerpt:
...- HER2 positive tumors (primary or metastatic) with overexpression HER2 determinated by IHQ +++ (IHQ3+) o IHQ ++ confirmed by FISH/SISH positive (IHQ2+/FISH+)...
Trial ID:
Source:
Title:
A Study of Herceptin (Trastuzumab) in Patients With Metastatic or Advanced Gastric Cancer With Disease Progression
Excerpt:
...- HER2 overexpression (IHC [2+] or [3+])....
Trial ID:
Source:
Title:
Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors
Excerpt:
...- Histologically confirmed HER2/neu-overexpressing (2+ or 3+) malignancy by any standardized assay (fluorescence in-situ hybridization allowed)...
Trial ID:
Less C2 evidence
Source:
Title:
Matched therapies for advanced gastric cancer based on genotype: A real-world study in China.
Published date:
05/19/2021
Excerpt:
...9 (30%) harbored HER2 mutation/overexpression (received RC48-ADC or trastuzumab, cohort B)…In cohort B, ORR was 44% (4/9), DCR was 78% (7/9), mPFS and mOS was 3.1 months and 5.5 months, respectively.
